Clover Health’s second quarter results were met with a positive market reaction, driven by strong Medicare Advantage membership growth and improved profitability. Management credited the quarter’s performance to the expansion of its Clover Assistant AI platform and disciplined focus on core markets, particularly New Jersey and Georgia. CEO Andrew Toy emphasized that “better clinical care leads to stronger cohort economics,” pointing to the impact of maturing member cohorts under the company’s technology-driven care model. The company also cited favorable medical cost trends and improvements in operating leverage as contributing factors.
Is now the time to buy CLOV? Find out in our full research report (it’s free for active Edge members).
Clover Health (CLOV) Q2 CY2026 Highlights:
- Revenue: $743.2 million vs analyst estimates of $728.2 million (55.6% year-on-year growth, 2% beat)
- Adjusted EPS: $0.07 vs analyst estimates of $0.05 (48% beat)
- Adjusted EBITDA: $40.92 million vs analyst estimates of $30.38 million (5.5% margin, 34.7% beat)
- The company lifted its revenue guidance for the full year to $2.96 billion at the midpoint from $2.87 billion, a 3.3% increase
- EBITDA guidance for the full year is $77.5 million at the midpoint, above analyst estimates of $58.44 million
- Operating Margin: 3.8%, up from -2.2% in the same quarter last year
- Customers: 157,309, up from 155,773 in the previous quarter
- Market Capitalization: $2.33 billion
While we enjoy listening to the management’s commentary, our favorite part of earnings calls is the analyst questions. Those are unscripted and can often highlight topics that management teams would rather avoid or topics where the answer is complicated. Here is what has caught our attention.
Our Top 5 Analyst Questions From Clover Health’s Q2 Earnings Call
- Richard Close (Canaccord Genuity) asked about Clover Assistant coverage in New Jersey and Georgia’s recent member cohorts. Interim CFO Clay Thornton explained engagement is slightly below the company average but improves as members stay longer, trending toward the two-thirds mark.
- Richard Close (Canaccord Genuity) inquired about the breakdown of members transitioning from year one to year two, and year two to year three. Thornton provided cohort percentages and highlighted the expected shift to more mature, higher-margin members in 2027.
- Richard Close (Canaccord Genuity) questioned the sequential decline in SG&A expenses. Thornton clarified that first quarter expenses included one-time, non-recurring items, and the second quarter reflected a more normalized expense base.
- Jonathan Yong (UBS) asked how management approached 2027 bids and whether recent cost trends or market disruption were factored in. Thornton explained bids were balanced, with cohort maturation and expected market disruption both considered.
- Jonathan Yong (UBS) probed the sustainability of high star ratings. CEO Andrew Toy stated that maintaining high ratings remains a focus, supported by investments in technology and clinical quality, but final outcomes will depend on upcoming plan previews.
Catalysts in Upcoming Quarters
Moving forward, our analysts will be monitoring (1) the continued maturation and retention of member cohorts managed under Clover Assistant, (2) progress in scaling operational automation and back-office AI initiatives to drive margin improvement, and (3) changes in the competitive and regulatory landscape—including CMS decisions on star ratings and any further market disruptions. Results in these areas will be critical for sustaining momentum into 2027 and beyond.
Clover Health currently trades at $4.43, up from $4.14 just before the earnings. Is the company at an inflection point that warrants a buy or sell? The answer lies in our full research report (it’s free).
The Best Stocks for High-Quality Investors
ONE MORE THING: Top 5 Growth Stocks. The biggest stock winners almost always had one thing in common before they ran. Revenue growing like crazy. Meta. CrowdStrike. Broadcom. Our AI flagged all three. They returned 315%, 314%, and 455%, respectively.
Find out which 5 stocks it’s flagging this month — FREE. Get Our Top 5 Growth Stocks for Free HERE.
Stocks that have made our list include now familiar names such as Nvidia (+1,460% between June 2020 and June 2025) as well as under-the-radar businesses like the once-micro-cap company Kadant (+214% between June 2020 and June 2025). Find your next big winner with StockStory today.
